Merck Serono Japan Launches Colon Cancer Drug Erbitux
This article was originally published in PharmAsia News
Executive Summary
Merck KGaA Japanese subsidiary Merck Serono Japan launched colon cancer drug Erbitux (cetuximab) Sept. 19. The company is marketing the drug under a joint promotion agreement with Bristol-Myers Squibb. The drug is indicated to treat progressive and relapsing colon cancers. As Japanese diets are increasingly westernized, colon cancers cases are on the rise. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.